Sickle Cell Disease news and research updates
Research readouts, treatment and access decisions, and community updates for people living with sickle cell disease and the people who care for them — each one dated, with a link to the original source where there is one.
31 articles match your filtersFree, no login required
Looking for earlier coverage? Browse the news archive.
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
The drug, pociredir, was being developed as an oral treatment for sickle-cell disease, an inherited blood disorder that can cause pain, anemia, organ damage and reduced life…
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik®(tazemetostat) and the product’s subsequent global withdrawal on…
Sickle Cell Anemia Testing and Screening Market Report Scope & Overview:
Sickle Cell Anemia Testing and Screening Market was valued at USD 494.8 million in 2025 and is expected to reach USD 1,579 million by 2035, growing at a CAGR of 12.30% from…
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
Agios Pharmaceuticals AGIO executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a…
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
Agios Pharmaceuticals AGIO announced that it has submitted a supplemental new drug application (sNDA) to the FDA seeking accelerated approval for the label expansion of its lead…
Sickle Cell Disease Clinical Fellow
Our mission is to train the next generation of providers with expertise in the care of individuals with sickle cell disease (SCD) throughout their lifespan. Objectives: 1. To…
Sickle cell disease after Casgevy: seven companies to watch in 2026
Casgevy’s approval changed the sickle cell disease landscape. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, the therapy showed that the disease could be tackled at…
Sickle Cell Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 55+ Key Companies | DelveInsight
DelveInsight’s “Sickle Cell Disease Pipeline Insights 2026” report provides comprehensive insights about 55+ companies and 60+ drugs in the Sickle Cell Disease Competitive…
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
Shares of Agios Pharmaceuticals AGIO declined sharply by 23% on Monday after Novo Nordisk NVO announced positive top-line data for its investigational drug, etavopivat, for the…
Anaemia
Anaemia is a common condition characterised by a lower-than-normal number of red blood cells or haemoglobin in the blood. Anaemia is a major health concern in India and is a…
India Sickle Cell Anaemia Market
As per analysis, the India Sickle Cell Disease Market is projected to grow from USD 0.259 Billion in 2024 to USD 0.294 Billion in 2025, ultimately reaching USD 0.92 Billion by…
Vindman Introduces Bill to Restore Crucial Funding for Sickle Cell Disease Research
Washington, D.C. — U.S. Representative Eugene Vindman (Va.-07) introduced legislation to restore staff and funding for the Centers for Disease Control and Prevention’s Sickle Cell…